ZNF626 Inhibitors
Chemical inhibitors of ZNF626 can affect its activity through various mechanisms impacting different cellular pathways. Palbociclib, a CDK4/6 inhibitor, can arrest the cell cycle, which may reduce the transcriptional activity of ZNF626 by limiting the availability of substrates required during the cell cycle. Another agent, Trichostatin A, is a histone deacetylase inhibitor that can modify chromatin structure, potentially decreasing the recruitment or binding efficiency of ZNF626 to gene promoters. Similarly, MG-132, a proteasome inhibitor, can lead to an accumulation of ubiquitinated proteins, which can sequester ubiquitin molecules necessary for ZNF626's function, thus indirectly inhibiting its activity.
LY294002, a PI3K inhibitor, can affect the PI3K/Akt pathway and alter transcription where ZNF626 may act as a co-regulator. MEK inhibitors such as PD98059 and U0126 can reduce the activity of ZNF626 if it is involved in processes regulated by the MAPK/ERK pathway. SB203580, a p38 MAPK inhibitor, and SP600125, a JNK inhibitor, can impact the MAPK and JNK signaling pathways, respectively. If ZNF626 participates in cellular responses mediated by these pathways, the activity of ZNF626 can be reduced. Y-27632, a ROCK inhibitor, can interfere with cellular processes dependent on ROCK signaling that may involve ZNF626. GW4869, an inhibitor of neutral sphingomyelinase, can alter sphingolipid signaling pathways that involve ZNF626. Lastly, rapamycin, an mTOR inhibitor, can suppress pathways regulated by mTOR that may involve ZNF626, and WZB117, which inhibits glucose transporter 1, can disrupt metabolic processes and indirectly affect the function of ZNF626 by altering the metabolic state of the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a CDK4/6 inhibitor. ZNF626, as a zinc finger protein, may be involved in transcription regulation that could be cell cycle-dependent. Inhibiting CDK4/6 can arrest the cell cycle, potentially reducing the transcriptional activity of proteins like ZNF626 by limiting its substrate availability during the cell cycle. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. By changing the acetylation status of histones, it can alter the chromatin structure and potentially decrease the binding efficiency or recruitment of DNA-binding proteins like ZNF626 to their target gene promoters. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 is a proteasome inhibitor that can increase the levels of ubiquitinated proteins. This can lead to a sequestration of ubiquitin molecules, which might be necessary for the function of ZNF626, thereby indirectly inhibiting its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. If ZNF626 is involved in any PI3K/Akt pathway-mediated transcription, inhibition of PI3K could reduce the transcriptional activity where ZNF626 is a co-regulator, thereby inhibiting its function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. If ZNF626 functions in any processes that are regulated by the MAPK/ERK signaling, inhibiting MEK could reduce ZNF626's activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. Inhibition of p38 MAPK can lead to altered transcription regulation. If ZNF626 is involved in p38 MAPK pathway-regulated gene expression, then inhibiting this kinase could indirectly inhibit the function of ZNF626. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, which impacts the JNK signaling pathway. If ZNF626 is a participant in cellular responses mediated by JNK signaling, inhibition of JNK could lead to a reduction in ZNF626 activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor, which may interfere with cytoskeleton organization and cell motility. If ZNF626 has a role in cellular processes that are dependent on ROCK signaling, inhibiting ROCK could indirectly inhibit the function of ZNF626. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is another MEK inhibitor, which could be used to confirm the results seen with PD98059. If ZNF626's activity is regulated by the MAPK/ERK pathway, U0126 could further validate the inhibition of MEK as a method for reducing ZNF626 function. | ||||||
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $199.00 $599.00 | 24 | |
GW4869 is a neutral sphingomyelinase inhibitor, which can impact sphingolipid signaling pathways. If ZNF626 is involved in any processes regulated by these pathways, inhibiting neutral sphingomyelinase with GW4869 could lead to an indirect inhibition of ZNF626's activity. | ||||||